Andrea García Esnaola adjusts the settings on a spectrometer, her eyes fixed on the molecular structure of a synthetic protein that could one day transform how we treat liver disease. At CIC biomaGUNE in Spain, García Esnaola and her team, led by Ikerbasque Research Professor Aitziber L. Cortajarena, have engineered a groundbreaking hybrid therapy—binding a lab-designed protein to gold nanoclusters made of just six atoms—that precisely targets Hsp90, a protein that drives liver fibrosis and cancer. In mice, this innovative treatment not only reduced scar tissue and tumor growth but did so with minimal side effects, offering a beacon of hope for the 3.3% of people worldwide living with advanced liver fibrosis and the hundreds of thousands lost each year to hepatocellular carcinoma.
Liver disease often begins silently, progressing from inflammation to irreversible scarring and, too often, to cancer. With 830,000 deaths globally in 2020 alone from liver cancer, the need for precise, effective therapies has never been greater. The Cortajarena team’s approach stands out because it combines therapy and diagnostics in one: the gold nanoclusters allow researchers to track the drug’s journey through the body, revealing exactly where it accumulates. This dual function—treatment and imaging—means doctors could one day monitor response in real time, adjusting care as needed.
The synthetic protein acts like a key fitting into the Hsp90 “lock,” blocking the signals that drive fibrosis and tumor growth. In diseased livers, where Hsp90 is overproduced, this intervention halts the cascade of damage. The results were striking: treated mice showed reduced levels of disease-triggering molecules and a noticeable decline in collagen buildup—the hallmark of scarring. In cancer models, tumors shrank in both number and size, confirmed through advanced imaging and molecular analysis. Perhaps most promising, the hybrid material provoked only a low immune response, a critical factor for long-term safety and repeat dosing.
But the innovation doesn’t stop at gold. The protein’s design allows it to bind not just to gold, but to other metals like iron or gadolinium, opening the door to real-time monitoring via MRI or other imaging techniques—without needing separate contrast agents. As Cortajarena explains, this adaptability could turn a single therapeutic into a full platform for diagnosis, treatment, and tracking.
While human trials are still ahead, this work marks a leap forward in nanomedicine. By merging synthetic biology with nanotechnology, the team has created more than a drug—it’s a smart system, designed to see, heal, and adapt. For millions facing the quiet progression of liver disease, that kind of intelligence could make all the difference.